Research programme: Duchenne muscular dystrophy gene therapies - Suzhou GenAssist Therapeutics
Alternative Names: GEN60xLatest Information Update: 10 Jun 2024
At a glance
- Originator Suzhou GenAssist Therapeutics
- Class Gene therapies
- Mechanism of Action Dystrophin expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Duchenne muscular dystrophy
Most Recent Events
- 27 May 2024 Early research in Duchenne muscular dystrophy in China (Parenteral) prior to May 2024 (Suzhou GenAssist Therapeutics pipeline, May 2024)
- 02 May 2024 Suzhou GenAssist Therapeutics has a worldwide patent pending for 'gene editor for disease treatment and nucleic acid pharmaceutical composition for anti-fibrosis inhibitor'